Clinical Trials Directory

Trials / Completed

CompletedNCT06975085

Understanding and Addressing Rejection of Personalized Breast Cancer Risk Information: Administrative Supplement Study

Understanding and Addressing Rejection of Personalized Breast Cancer Risk Information in Women

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
781 (actual)
Sponsor
University of Colorado, Denver · Academic / Other
Sex
Female
Age
39 Years – 74 Years
Healthy volunteers
Not accepted

Summary

The Understanding and Addressing Rejection of Personalized Cancer Risk Information study is a longitudinal study conducted to understand the nature of phenomenon of personalized cancer risk rejection in the context of mammography screening.

Detailed description

The Understanding and Addressing Rejection of Personalized Cancer Risk Information study seeks to understand the nature of the phenomenon of personalized cancer risk rejection in the context of mammography screening by testing hypotheses about why women reject their risk estimate and the influence of rejection on screening intentions. The Breast Cancer Risk Assessment Tool (BCRAT) will be used to asses participant's breast cancer risk. This model is designed to estimate breast cancer risk in women 35-84, and uses the following predictors: 1) age, 2) age at first menstrual period, 3) age at first live birth, 4) first-degree relatives with breast cancer, 5) previous breast biopsy with atypical hyperplasia, and 6) race/ethnicity. Participants will be required to complete a survey in which they receive their BCRAT model risk estimate and respond to that risk estimate.

Conditions

Interventions

TypeNameDescription
BEHAVIORALPresentation of a personal breast cancer risk estimateParticipants answer questions that are used to calculate their personal breast cancer risk using the Gail Model. This risk estimate is presented to participants using written text and an icon array.

Timeline

Start date
2025-04-16
Primary completion
2025-04-30
Completion
2025-04-30
First posted
2025-05-16
Last updated
2026-02-12

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT06975085. Inclusion in this directory is not an endorsement.